Disrupting Dengue with an Emerging Markets Launch Strategy Harvard Case Solution & Analysis

Disrupting Dengue with an Emerging Markets Launch Strategy Case Solution

The business invested 20 years and also invested $1.7 billion to establish Dengvaxia, taking numerous high-risk choices and making compromises along the way. The scenario feature the stakeholder interdependencies and also unpredictabilities that stayed as the vaccine execution program sneaked more detailed. It might possibly provide a plan for various other if effectively solved.

Sanofi Pasteur's freshly authorized dengue vaccine, Dengvaxia, was uncommon because it was introduced in the Philippines and various other at-risk nations. By opting to "turn the design" - launch in a developing market setting rather than industrialized markets - it needed to conquer different challenges throughout the worth chain, from enrollment to funding to provide.

PUBLICATION DATE: September 26, 2016

This is just an excerpt. This case is about LEADERSHIP & MANAGING PEOPLE

Disrupting Dengue with an Emerging Markets Launch Strategy Case Solution Other Similar Case Solutions like

Disrupting Dengue with an Emerging Markets Launch Strategy

Share This